Shop
Pay BillClinical Trials and Clinical Research
Our dedicated Clinical Research Department offers innovative clinical research trials dedicated to fighting disease and improving the health and wellness of our patients.
Clinical trials include:
- Psoriasis
- Hair Loss
- Vitiligo
- Atopic Dermatitis (Eczema)
- Prurigo Nodularis
- Hidradenitis Suppurativa
- Alopecia Areata
- Actinic Keratosis
- Gorlin Syndrome
What our patients say
” I wanted to let you know how much I appreciated all your help with my Psoriasis clinical trial. I had Psoriasis for over seven years and after just a few weeks working with you and Dr. Bagel, my skin is clear. The program was over a twelve week time period and as time went by I used less and less of the medication and my skin looks and feels great. “
” I was enrolled in a four-month clinical trial and the results were very good. I have had psoriasis for many years and have seen many dermatologists and tried several treatments. For the first time, I have been treated successfully. Very happy with the overall experience and would highly recommend them to anyone. “
” I was at the end of my rope with unbearable eczema flare ups. Due to my participation in a research studies, I was offered a new medication that finally gave me much needed relief. “
Why participate?
Clinical trials include:
- Access to the latest medical treatments
- No cost to enroll
- No insurance needed
- You may be eligible to receive reimbursement for time & travel
- Receive support from a dedicated team of dermatology professionals
World-class Leadership
Our Principal Investigators are award-winning dermatologists and are involved in every aspect of the patient visit
Featured Articles
Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that the 12-month clinical data related to AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne, was presented at the Annual Fall Clinical Dermatology Conference, which took place October 20-23 in Las Vegas, Nevada.
Current clinical studies show that after three 30-minute treatment sessions, 90% of patients had a visible improvement in their acne at 6 months.1 New 12-month clinical findings show this improvement increases to 92%,2 confirming the continual improvement of acne clearance and skin quality over time. Studies also demonstrate that three-fourths of patients showed a 2+ IGA score improvement and two-thirds of patients were assessed as clear or almost-clear 12 months after their final treatment session.3
Read More
The Psoriasis Treatment Center of New Jersey, a part of Schweiger Dermatology Group, has recently revealed encouraging findings from an open-label clinical trial involving tapinarof (VTAMA) cream 1%, in conjunction with injectable biologics for the treatment of adult plaque psoriasis. The trial aimed to achieve the National Psoriasis Foundation's (NPF) treat-to-target goal, reducing psoriasis to 1% body surface area (BSA) or less within 3 months.
Conducted at a single center, the observational study enrolled 30 patients with at least 3% BSA who had been on stable biologic therapy for a minimum of 26 weeks. Eligible patients received tapinarof cream once daily for 12 weeks, in addition to their biologic regimen. Following the discontinuation of tapinarof cream at week 12, patients returned at week 16 for safety assessments and to evaluate maintenance response, with patient-reported outcomes collected from baseline through week 16.
